Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1040020230140010018
International Journal of Pain
2023 Volume.14 No. 1 p.18 ~ p.22
The Effect of Mirogabalin on the Treatment of Intractable Postherpetic Neuralgia Not Responding Appropriately to Pregabalin: A Case Report
Jeong Jeong

Hwang In-Eob
Woo Sung-Won
Moon Jee-Youn
Abstract
Postherpetic neuralgia (PHN) is the most common but challenging complication of herpes zoster due to long-lasting intractable neuropathic pain. Routine pharmacologic treatments of PHN include anticonvulsants (e.g., gabapentin, pregabalin), antidepressants (e.g., amitriptyline), opioids (e.g., oxycodone, morphine). However, those medications have limitations due to side effects inclusive of peripheral edema, nausea, vomiting and somnolence, or insufficient analgesic effect. Mirogablin, a novel voltage-gated calcium channel (VGCC) selective ¥á2¥ä ligand, has been recently approved as a drug to treat peripheral neuropathic pain. In this case report, we represent a 77-year-old patient with intractable PHN who achieved successful pain relief with intake of mirogabalin with less side effects.
KEYWORD
anticonvulsant, gabapentinoid, mirogabalin, neuropathic pain, postherpetic neuralgia
FullTexts / Linksout information
Listed journal information